. Over the past decade, an enormous number of studies (>100) have focused on the role of nitric oxide (NO) in myocardial ischemia. It is important to distinguish the function of NO in unstressed (nonpreconditioned) myocardium from its function in preconditioned myocardium (i.e. myocardium that has shifted to a defensive phenotype in response to stress). Of the 92 studies that have examined the role of NO in modulating the severity of ischemia/reperfusion injury in non-preconditioned myocardium, the vast majority [67 (73%)] have concluded that NO (either endogenous or exogenous) has a protective effect and only 11 (12%) found a detrimental effect. The proportion of studies supporting a cytoprotective role of NO is similar in vivo [35 (71%) out of 49] and in vitro [32 (74%) out of 43]. With regard to the delayed acquisition of tolerance to ischemia [late preconditioning (PC)], overwhelming evidence indicates a critical role of NO in this phenomenon. Specifically, enhanced biosynthesis of NO by eNOS is essential to trigger the late phase of ischemia-induced and exerciseinduced PC, and enhanced NO production by iNOS is obligatorily required to mediate the anti-stunning and antiinfarct actions of late PC elicited by five different stimuli (ischemia, adenosine A 1 agonists, opioid 1 agonists, endotoxin derivatives and exercise). Thus, NO plays a dual role in the pathophysiology of the late phase of PC, acting initially as the trigger and subsequently as the mediator of this adaptive response ("NO hypothesis of late PC"). The diversity of the PC stimuli that converge on iNOS implies that the upregulation of this enzyme is a central mechanism whereby the myocardium protects itself from ischemia. The NO hypothesis of late PC has thus revealed a cytoprotective function of iNOS in the heart, a novel paradigm which has recently been extended to other tissues, including kidney and intestine. Other corollaries of this hypothesis are that the heart responds to stress in a biphasic manner, utilizing eNOS as an immediate but short-term response and iNOS as a delayed but long-term defense, and that the fundamental difference between non-preconditioned and late preconditioned myocardium is the tissue level of iNOS-derived NO, which is tonically higher in the latter compared with the former. Hence, late PC can be viewed as a state of enhanced NO synthesis.
Introduction
1 and 2). Most of these investigations have The discovery that nitric oxide (NO), an air polutilized a pharmacological approach to either inlutant, serves as a mediator of biological processes hibit endogenous NOS activity with -arginine anahas been one of the most remarkable advances in logs during myocardial ischemia/reperfusion or biomedical research in the 20th century. Over the enhance NO availability by administering NO past 15 years, a deluge of articles have implicated donors (e.g. SNAP, DETA/NO, nitroglycerin) or prethis ubiquitous molecule in virtually every physiocursors (-arginine) prior to, during, or after ischlogical and pathophysiological process. It is thus emia; a minority of studies have utilized genetically not surprising that the role of NO in myocardial engineered mice deficient in eNOS or iNOS. ischemia and in myocardial preconditioning (PC) Even a cursory analysis of these studies dispels has become the focus of considerable interest. Intwo widely held misconceptions. First, it has been deed, this has been one of the fastest growing areas asserted that the role of NO in myocardial ischemia in basic cardiovascular research in recent times, is deleterious (due to its putative pro-oxidant acand one that has yielded important new insights tions) and that the literature on this topic is coninto the molecular basis of myocardial ischemia/ troversial, due to the inconsistency of the results reperfusion injury. More than 100 articles have obtained by different investigators. The review of focused on this issue over the past decade. The the literature summarized in Tables 2 and 3 , howpurpose of this essay is to review this enormous ever, does not support this interpretation. Of the body of information and distill it to few, essential 92 studies that have examined the role of NO in concepts that are widely supported by the literature. myocardial ischemia, 67 (73%) have concluded Particular emphasis is placed upon the carthat NO (either endogenous or exogenous) has a dioprotective properties of inducible NO synthase protective effect (Tables 1 and 2 ; Fig. 1 ). This (iNOS), an enzyme whose function in the cardioconclusion was based upon the observation that vascular system was enigmatic until recently and inhibition or genetic ablation of endogenous NOS that has now been identified as a major defensive activity exacerbated myocardial ischemia/ mechanism against ischemia.
reperfusion injury and that exogenous supConceptually, it is important to distinguish the plementation of NO (via NO donors or NO prerole of NO in modulating ischemia/reperfusion incursors) ameliorated the severity of such injury. jury in unstressed (non-preconditioned or naïve)
The protective effect of NO was apparent in the myocardium from the role of NO in preconditioned setting of both regional and global ischemia, in myocardium (i.e. myocardium that has shifted to different species, and using either infarction or a defensive phenotype in response to stress). Bestunning as the endpoint. Inhibition or genetic cause the phenomenon of PC encompasses two ablation of NOS was found to have no discernible temporally and pathophysiologically distinct phases effect on ischemia/reperfusion injury in 18 studies with widely different clinical implications, 1,2 the role (20%) and to be detrimental in 11 studies (12%). of NO in the early and late phases of PC needs to (In one investigation, 95 -NA reduced heart rate be examined separately.
significantly during ischemia; therefore, conclusions regarding the effect of -NA on infarct size in this study cannot be made. This study is not included in Table 1 or in Figure 1 .)
Role of Nitric Oxide in Modulating
Another commonly held misconception is that
Ischemia-Reperfusion Injury in Non-
in vitro studies tend to favor a detrimental role preconditioned Myocardium of NO in myocardial ischemia/reperfusion injury whereas in vivo studies suggest a protective role. Over the past 10 years, an enormous number of Again, the analysis of the literature does not support studies (at least 92) have examined the role of NO in modulating the severity of ischemia/reperfusion this concept. As shown in Tables 1 and 2 and in Endogenous Beneficial 50 H1105-H1112 § Although -NA did not exacerbate stunning in unpaced hearts, it did so when heart rate was kept constant by pacing. In one investigation, 95 -NA reduced heart rate significantly during ischemia; therefore, conclusions regarding the effect of -NA on infarct size in this study cannot be made. This study is not included in Table 1 cytoprotective role of NO (either endogenous or exogenous) in myocardial ischemia/reperfusion inhave concluded that NO is protective (i.e. that inhibition of NO biosynthesis is detrimental and/or jury, both in vitro and in vivo. The fact that only a small fraction (12%) of the published articles rethat enhanced NO availability is beneficial); only four in vivo studies have concluded that NO is ported a deleterious effect of NO suggests that this finding is not widely reproducible and may be detrimental. This breakdown is not different among the in vitro studies, where 74% (32 out of 43) have model-dependent. Considering the numerous differences among investigations with respect to exconcluded that NO is protective during myocardial ischemia/reperfusion. perimental settings, species, experimental protocols, dosages of drugs etc., a certain degree of variance In summary, the overwhelming majority of the 92 studies published in the past decade supports a in outcomes should be expected. Endogenous No effect 93 H2752-H2765 † Spontaneous NO release had no effect; VEGF-induced NO release protective. # -arginine beneficial before or during ischemia, detrimental during reperfusion.
§ -NA had no effect at 4.6 mol/l but was protective at 46 mol/l. * NOS inhibitors had no effect but abolished endothelin-1 protection.
concluded that inhibition of endogenous NO syn- 93 found that -NAME abrogated the were not blocked by NOS inhibitors in open-chest dogs 10 and isolated rat hearts; 69 in contrast, Richard beneficial effects of ischemic PC in isolated rat hearts and that these effects could be mimicked by et al. 19 reported that acetylcholine-induced early PC was blocked by -NA in open-chest rats. pretreatment with nitroprusside or SNAP (but not -arginine). With respect to pacing-induced early One important form of pharmacologically-induced early PC is that elicited by NO donors. Al-PC, Ferdinandy et al. 71 reported in isolated rat hearts that the protective effects of this form of early PC though the studies reviewed above indicate that occlusion elicited an infarct-sparing effect in conscious rabbits, although the magnitude of this early PC effect was less than that of the late PC effect observed 24-72 h after nitroglycerin. Interestingly, Banerjee et al. 101 found that the same dose of i.v. nitroglycerin failed to induce an early PC effect against myocardial stunning, which is consistent with the notion that ischemia itself does not induce early PC against stunning.
Role of Nitric Oxide in the Early Phase
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In summary, the preponderance of the evidence indicates that endogenous biosynthesis of NO is not add up because two investigations 63, 75 concluded that endogenous NO is detrimental whereas exogenous NO is beneficial, one study 70 concluded that exogenous NO can be either beneficial or detrimental depending on the timing of treatment, and one investigation 73 concluded
Role of Nitric Oxide in the Late Phase of
that spontaneous NO release has no effect but VEGF-
Preconditioning
induced NO release is protective (see Table 2 ). Therefore, each of these four studies 63, 70, 73, 75 is counted twice under
In addition to an early phase of protection that the in vitro category.
lasts 1-2 h, ischemic PC elicits a late phase of cardioprotection that appears 12-24 h after the stimulus and persists for 72 h (reviewed in reference endogenous NO is not necessary for ischemia-induced early PC, considerable evidence suggests that 2). [104] [105] [106] Unlike the early phase, which protects against infarction but not against stunning, the administration of exogenous NO can elicit an early PC-like protection. Nakano et al. 86 demonstrated in late phase of ischemic PC protects against both infarction and stunning. 2, 103 In view of this, and in isolated rabbit hearts subjected to a 30-min coronary occlusion followed by 2 h of reperfusion that view of the sustained duration of the protective effect, the late phase of PC may have greater clinical pretreatment with SNAP in lieu of ischemia elicited a powerful infarct-sparing effect comparable to that relevance than the early phase. The late phase of PC can be elicited not only by ischemia but also elicited by ischemic PC. The protective effects of SNAP were unlikely to be due to continued presence by various pharmacologic and non-pharmacologic manipulations, including activation of adenosine of the drug during ischemia, as SNAP was removed 10 min before the coronary occlusion. SNAP-in-A 1 and A 3 receptors, opioid 1 receptors, bradykinin B 2 receptors, 107 administration of NO donors, endoduced early PC was abrogated by MPG and chelerythrine, indicating that its cardioprotective toxin, endotoxin derivatives and cytokines, and exposure to exercise. 2 Although early and late PC effects are mediated by generation of ROS and activation of PKC-a signaling pathway analogous can be triggered by the same stimuli, the mechanisms involved are fundamentally different: early to that involved in NO-induced late PC. [100] [101] [102] Similarly, Hill et al. 99 found that i.v. infusion of nitro-PC results from a rapid (and short-lived) posttranslational modification of pre-existing proteins, glycerin ending 1 h prior to a 30-min coronary whereas late PC is due to de novo synthesis of is the same signaling pathway that is responsible for the development of ischemiacardioprotective proteins secondary to genetic reprogramming of the heart. 2 induced late PC. 2 Upregulation of iNOS after ischemic PC also requires activation of the In recent years, considerable evidence has accumulated which indicates a pivotal role of NO in JAK-STAT signaling pathway (specifically, of JAK1, JAK2, STAT1 and STAT3). 119 Thus, the late phase of PC induced by ischemia, pharmacologic manipulations, and exercise (Fig. 2) . 2, 108 at least two signaling pathways (PKC -Src/ Lck-NF-B and JAK1/2-STAT1/3) are inSince these studies have been reviewed in detail elsewhere, 2,108 only a synopsis of the salient concepts volved in the transcriptional activation of the iNOS gene following ischemic PC. Whether will be presented here. In discussing this topic, it is important to bear in mind the distinction between these two pathways act in parallel or in series remains to be determined. The fact that both the "triggers" of late PC (i.e. the molecular species that initiate this adaptation when a PC stimulus is NF-B and STAT1/3 are required to activate the iNOS gene is consistent with the notion applied) and the "mediators" of late PC (i.e. the molecular species that confer cardioprotection that multiple transcription factors, acting in an additive or synergistic manner, are neces-24-72 h after the PC stimulus Table 4 ), indicating that NO is an important chemical signal generated in response to myocardial ischemia/reperfusion) to form peroxynitrite whereby the heart shifts to a defensive phenotype upon exposure to ischemic or exercise (ONOO − ) which, in turn, could activate PKC either directly or via its reactive byproducts, stress.
(ii) The source of the NO that triggers late PC such as ·OH. 108 This latter scenario is supported by the finding that NO donor-induced during ischemia or exercise is most likely eNOS, because (1) the development of late PC activation of PKC can be blocked by the ONOO − and ·OH scavenger MPG. 100 Iris blocked by pretreatment with the nonselective NOS inhibitor -NA, but not with respective of the exact mechanism, the finding that the initiation of ischemia-induced late the relatively selective iNOS inhibitors aminoguanidine and S-methylisothiourea, 34 and (2) PC is blocked by both -NA 109,110 and MPG 120 suggests that both NO and ·O 2 − are necessary direct measurements of NOS activity have shown a burst of calcium-dependent NOS to trigger this phenomenon, either by reacting with one another or via independent (parallel) (eNOS and/or nNOS) activity immediately after the PC ischemia, which is abolished by mechanisms. (vi) Clinically relevant NO donors, such as nitrothe same dose of -NA that abrogates the development of late PC. 112 glycerin, can elicit late PC when given either by the i.v. route 99, 101 or by the transdermal (iii) Administration of NO donors (DETA/NO, SNAP, nitroglycerin) in lieu of ischemia elicits route. 99 The infarct-sparing effects of nitroglycerin are robust and persist for 72 h after a delayed cardioprotection against both myocardial stunning and infarction which is ina single i.v. infusion or after a single transdermal patch administration. 99 Furthermore, distinguishable from that elicited by ischemia (Table 4) . [99] [100] [101] [102] 113 Thus, NO is not only necesthe ability of nitroglycerin to elicit late PC is not hampered by the presence of tolerance to sary, but also sufficient to induce late PC. (iv) The signaling pathway whereby NO (either the hemodynamic actions of nitrates. 99 These findings support novel applications of nitrates endogenous or exogenous) induces late PC involves the generation of reactive oxygen for the prophylaxis of ischemic injury in patients. 2 species, 100 the activation of the isotype of protein kinase C, 102 ,114 the subsequent re-(vii) In addition to its role as a trigger of ischemiainduced late PC, NO also plays a critical role cruitment of Src and Lck tyrosine kinases, 114-116 and the activation of the transcription as a mediator of cardioprotection 24 h later (Table 5) . 34, [121] [122] [123] The NOS isoform responsible factor NF-B, 117 culminating in transcriptional activation of the iNOS gene. 118 This for generating the NO that confers car- − activate the isoform of PKC via mechanisms that remain to be elucidated. Both NO and ·O 2 − -derived ROS could directly activate PKC via nitrosylation and oxidative modification, respectively; alternatively, NO and ·O 2 − are known to react to form ONOO − which, in turn, could activate PKC . PKC activation then triggers a complex signaling cascade that involves Src and/or Lck tyrosine kinases and probably other kinases, leading to phosphorylation of I B and mobilization of the transcription factor NF-B. Both IKK-dependent serine phosphorylation (on residues 32 and 36) and IKK-independent tyrosine phosphorylation (on residue 42) of I B appear to be required for ischemic PC-induced activation of NF-B. Other transcription factors are most likely involved as well. In particular, ischemic PC has recently been found to activate JAK1 and JAK2 with subsequent tyrosine phosphorylation and activation of STAT1 and STAT3, which is essential for iNOS upregulation. Binding of NF-B and STAT1/3 to the iNOS promoter results in transcriptional activation of the iNOS gene and synthesis of new iNOS proteins, which leads to a phenotype characterized by tonically enhanced NO biosynthesis (preconditioned phenotype). There is evidence that post-translational modulation of iNOS by Src and/or Lck is important for iNOS activity on day 2. iNOS-derived NO, in turn, protects the myocardium from recurrent ischemia via mechanisms that remain unclear. One plausible mechanism is the activation of COX-2-dependent synthesis of cardioprotective prostanoids (e.g. PGE 2 and PGI 2 ). A similar activation of PKC and downstream kinases can be elicited pharmacologically by NO donors, adenosine A 1 agonists, 1 -opioid receptor agonists, endotoxin derivatives, and physical exercise, leading to a preconditioned phenotype that is similar to that elicited by an ischemic stress. An interesting corollary of this paradigm is that the heart possesses a feed-forward mechanism whereby eNOS-derived NO can upregulate iNOS (eNOS-dependent iNOS induction).
dioprotection is iNOS, as demonstrated by 115, 118, 119, 123, 124 and that inhibition of either iNOS protein expression 123 or iNOS activity 34, both pharmacological 34, 121, 122 and genetic 123 studies. The first documentation of the role 121, 122 completely abrogates the salubrious effects of late PC. iNOS is specifically upof iNOS as an obligatory mediator of late PC was provided in 1997. 34 Since then, several regulated in cardiac myocytes ( (Table 5) . Thus, iNOS-dependent In summary, the studies reviewed above support biosynthesis of NO appears to be a final coma complex paradigm in which two different NOS mon pathway whereby the heart protects isoforms are sequentially involved in the pathoitself in response to diverse stresses. 2, 108 physiologic cascade of late PC, with eNOS gen-(ix) In contrast to the three studies mentioned erating the NO that triggers late PC on day 1 [109] [110] [111] above, 125-127 one study in isolated hearts 134 and iNOS then generating the NO that protects has concluded that the protection afforded by against ischemia 24-72 h later. 34, [121] [122] [123] [125] [126] [127] [128] [129] [130] [131] [132] 133 adenosine A 1 receptor-induced late PC is not This led to the formulation in 1998 of the "NO iNOS-dependent (Table 5) .
hypothesis of late PC", 108 which states that NO (x) The precise mechanism whereby iNOS-deplays a dual role in the pathophysiology of the late rived NO protects against ischemia 24-72 h phase of PC, acting initially as the trigger and after a PC stimulus remains unknown, alsubsequently as the mediator of this adaptive rethough recent data indicate that this involves sponse. These two roles are interconnected, for it the activation of guanylate cyclase. 135 is the burst of NO production during the PC stimulus (xi) The upregulation of iNOS protein expression that causes increased expression and activity of and activity after the PC stimulus is modest, iNOS 24 h later. 112, 118 In the 3 years following its 112, 115, 118, 119, 123, 124 an order of magnitude less formulation, 108 the NO hypothesis of late PC has than that observed after a lethal dose of lipobeen convincingly validated by pharmacologic, biopolysaccharide. 123, 124 This is an important obchemical and molecular genetic evidence acservation, as it may explain the apparent cumulated in various models of cardiac adaptation, paradox whereby an enzyme known to pro- 34, [109] [110] [111] [112] [113] 118, [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] and thus should now be regarded duce cytotoxicity, such as iNOS, is recruited by as a proven hypothesis. The studies published to the heart to confer protection against ischemic date on the role of NO as a trigger and mediator of insults. Specifically, it has been proposed 123, 124 late PC are categorized in Tables 4 and 5 , and a that a relatively modest upregulation of iNOS, schematic illustration of the NO hypothesis of late such as during late PC, is cardioprotective PC is presented in Figure 2 . An interesting and whereas a massive upregulation of iNOS, such conceptually novel corollary of this paradigm is as during inflammation or septic shock, is that the heart possesses a feed-forward mechanism whereby eNOS-derived NO can upregulate iNOS detrimental. In vivo Exercise Infarction PC abolished 133 * Since the non-selective NOS inhibitor -NA was used, the role of cNOS v iNOS cannot be discerned.
(eNOS-dependent iNOS induction). 2 This is the opfocus attention on the pervasive role of NO in posite of what has been reported in other cell types, cardioprotection (Fig. 2) . Furthermore, the NO such as neutrophils and glial cells, where cNOShypothesis of late PC has led to a new understanding derived NO has been found to suppress the tranof the wisdom with which specific NOS isoforms scription of the iNOS gene via a negative feedback are used for specific purposes. This hypothesis premechanism. 136 dicts that the heart assigns different tasks to eNOS and iNOS in a manner that fits the different personalities of these two enzymes. 108 Since eNOS is constitutively expressed and its activity can be re-
Conceptual Implications of the Dual Role
cruited almost instantaneously by both calcium-
of Nitric Oxide in Late Preconditioning
dependent and calcium-independent mechanisms, 137 this protein is well suited for an immediate The recognition that NO serves both as a trigger and but brief reaction. iNOS, on the other hand, is a mediator of late PC 108 was somewhat surprising, as dormant in unstressed myocardium (where it is there is no a priori reason why the same molecule expressed at low levels) 112, 115, 119, 123, 124 but can be should perform both of these unrelated tasks. Nevertheless, this unexpected discovery has served to upregulated by stress; its activity is tonic (rather has impelled a radical reassessment of this view.
108
• Antagonism of -adrenergic stimulation
As indicated above, there is now solid evidence that
• Reduced contractility iNOS is a common mediator of the cardioprotective (Table 5 ; Fig. 2 ). The diversity of the PC stimuli that converge on Less likely iNOS implies that: (i) the upregulation of this protein
• Preserved endothelium-dependent vasodilation is a ubiquitous response of the heart to perceived
• Reduced "no reflow" threats; and (ii) generation of NO via iNOS is a
• Reduced leukocyte infiltration central mechanism whereby the myocardium pro-
• Reduced release of cytokines tects itself from impending ischemic challenges.
• Reduced expression of vascular cell adhesion Importantly, it is becoming apparent that the molecule-1 role of iNOS as a common pathway of late PC is not limited to the heart, since recent reports have extended this paradigm to other organs. Specifically, than pulsatile) and does not necessitate perturbation of Ca ++ levels or cellular homeostudies of late PC in the kidney 138 and intestine 139 indicate that induction of iNOS is a critical mechstasis. 137 Thus, iNOS is well suited for a delayed but sustained reaction. The mechanism of late PC has anism whereby ischemia triggers delayed protection in these tissues as well, suggesting that the iNOS been found to be consistent with the most effective utilization of the specific properties of eNOS and hypothesis, which was originally formulated in the context of cardiac PC, 108 may be broadly applicable iNOS. Indeed, the studies reviewed above indicate that when non-preconditioned myocardium is exoutside of the cardiovascular system. A fundamental role of iNOS in protecting against ischposed to a stress (i.e. to a perceived threat) such as ischemia, it mobilizes the already available eNOS emia is further supported by the finding that low oxygen tension induces iNOS in hepatocytes, 140 that for an immediate burst of NO biosynthesis to help deal with the emergency. At the same time, the iNOS expression increases in response to hypoxia in cardiac myocytes 141, 142 and in macrophages, 143 heart puts in place a strategy for dealing with the possible recurrence of this threat; specifically, it and that iNOS activity and expression are upregulated in atrial tissue obtained from cyanotic shifts to a preconditioned (defensive) phenotype by expressing iNOS, which will maintain elevated children with congenital heart defects. 144 Collectively, the evidence emerging from studies of late myocardial NO levels for a sustained period of time, thereby keeping the tissue protected from PC and from the other studies reviewed above suggests that iNOS is a hypoxia-responsive gene any possible similar threat, whose precise timing is unknown to the heart. In summary, the heart and that the activity of this enzyme is a generalized mechanism of defense against ischemic injury. responds to stress in a biphasic manner, utilizing eNOS as an immediate but short-term response and iNOS as a delayed but long-term defense.
Clinical Implications of the Nitric Oxide Hypothesis of Late Preconditioning Role of iNOS as a Cardioprotective
Besides its conceptual and pathophysiological re-
Protein and as a Ubiquitous Mediator of
verberations, the NO hypothesis of late PC has Late Preconditioning important therapeutic implications. As reviewed above, administration of NO donors, in the absence An important consequence of the NO hypothesis of late PC has been the identification of a novel funcof ischemia, can faithfully recapitulate both the molecular and the functional aspects of the late tion for iNOS as a cytoprotective protein. The role of this enzyme in the cardiovascular system has phase of ischemia-induced late PC in experimental animals. [99] [100] [101] [102] 113 In keeping with these data, recent mechanism is unknown, many hypotheses have been put forth ( 146 Thus far, nitrates have been used mainly for their antianginal and preload-reoxygen consumption, [168] [169] [170] [171] [172] [173] and opening of sarcolemmal K ATP channels. [174] [175] [176] The reduced Ca 2+ ducing properties. The finding that nitroglycerin elicits late PC in patients 145 supports the novel idea current may alleviate the Ca 2+ overload associated with acute myocardial ischemia, which is one of that nitrates could also be used as a PC-mimetic therapy for the prophylaxis of ischemic myocellular the major mechanisms of ischemic injury. 177 The recent demonstration that NO donors facilitate the injury in such settings as stable and unstable angina, cardiac surgery, cardiac transplantation and activation of mitochondrial K ATP channel opening by diazoxide and partially activate the channel coronary angioplasty. This new application of nitrates could be as important as, or perhaps even directly 178 supports the hypothesis that the cardioprotective effects of NO may be mediated, at least more important than, their current use in patients with coronary artery disease. Most agents that elicit in part, by increased activity of the mitochondrial channels. Mitochondrial K ATP channel activity, howa late PC-like protection in experimental studies are not clinically applicable, for various reasons. [147] [148] [149] [150] [151] [152] ever, cannot entirely account for the salubrious actions of NO because K ATP channel antagonists fail In contrast, nitrates are generally well tolerated. Although numerous clinical trials have examined to block the anti-stunning effects of iNOS-dependent late PC in rabbits. 179 An interesting mechanism of the effect of nitrates in acute coronary syndromes, in all of these studies treatment was started either action was recently proposed by Heusch et al. 94 who found that endogenous NO preserves contractile during or immediately after the index ischemic insult (see, for example, references 153 and 154).
function during ischemia through preservation of calcium responsiveness at no additional energetic In view of the experimental and clinical evidence pointing to the ability of nitrates to trigger late PC, cost. Another possibility is that NO protects by virtue of its antioxidant properties, specifically, its it might be fruitful to re-explore the role of nitrate therapy given before the onset of ischemia.
ability to attenuate the deleterious free radical actions of ·O 2 −180 and to terminate ONOO − -mediated In addition, the discovery that iNOS is a common mediator of the protection afforded by so many lipid radical chain propagation 181 (Table 6) . A previously unrecognized mechanism by which different types of late PC supports the idea that genetic or pharmacologic strategies that upregulate NO protects the ischemic myocardium has recently emerged, namely, stimulation of cyclooxygenase-2 this protein could be fruitfully exploited to protect the ischemic heart in patients. In this context, (COX-2) activity with consequent production of cytoprotective prostanoids such as prostaglandin recent experimental data indicate that gene transfer of either eNOS 155 or iNOS 156 can replicate the power-(PG)E 2 and PGI 2 . 182 This mechanism was identified by Shinmura et al. 182, 183 in the setting of late PC, ful infarct-sparing actions of ischemic PC, suggesting that NOS gene therapy could be an effective where inhibition of iNOS was found to abrogate prostanoid synthesis 182 whereas inhibition of COXstrategy for combating ischemia/reperfusion injury by increasing local myocardial NO levels without 2 did not affect iNOS activity 182 but resulted in loss of protection, 183 indicating that COX-2 activity is the need for continuous administration of NO donors and without systemic NO-dependent hemodriven by iNOS-derived NO and is obligatorily required for iNOS to exert its cardioprotective effects. dynamic changes.
Whether COX-1 or COX-2 activity also mediates the cardioprotective effects of NO in non-preconditioned myocardium is unknown. NO has also been suggested to protect against
Mechanism for the Cardioprotective
lethal ischemia/reperfusion injury by preventing
Effect of Nitric Oxide
the impairment of endothelium-dependent coronary vasodilation 184 and by reducing the "no reThe precise mechanism(s) whereby NO protects the myocardium against ischemia/reperfusion injury flow" phenomenon, 6 the infiltration of leukocytes, 185 the release of cytokines, 186 and the exremains unclear. As always is the case when a pression of vascular cell adhesion molecule-1 analysis, the fundamental difference between nonpreconditioned and late preconditioned myo-(VCAM-1) 187 (Table 6 ). These latter hypotheses, however, are less plausible because the "no reflow" cardium appears to be the tissue level of NO, which is tonically higher in the latter (as a result of iNOS phenomenon and the inflammatory response to ischemia/reperfusion are likely to be a consequence, upregulation) compared with the former. Thus, late PC can be viewed as a state of enhanced NO output. rather than a cause, of ischemic myocellular death. Clearly, considerable additional work will be necesIn contrast to the late phase of PC, generation of NO is not necessary for the development of the sary to identify the mechanism of action of this ubiquitous mediator.
early phase of ischemia-induced PC; nevertheless, exogenous NO can elicit an early protective effect similar to the early phase of ischemic PC. Taken together, the evidence reviewed in this article indicates that NO plays a fundamental bioConclusions logical role in protecting the heart against ischemia/ reperfusion injury. Far from being detrimental, as An overwhelming body of evidence accumulated over the past decade demonstrates that biosynthesis sometimes has been proposed, biosynthesis of NO is instead critical to preserve tissue function and of NO by constitutive NOS (endogenous NO) plays an important role in alleviating the severity of both viability during an ischemic insult. The recognition that production of NO represents nature's own reversible (myocardial stunning) and irreversible (myocardial infarction) damage incurred during protective mechanism against ischemia offers fertile practical implications. Many opportunities loom on ischemia/reperfusion in the unstressed (non-preconditioned) heart. A similar salubrious effect can the horizon for enhancing NO availability in a manner that would be therapeutically desirable. be produced by exogenous NO, given by means of NO-releasing agents or NO precursors. In addition, Experimental studies have shown that NO donors in themselves, in the absence of ischemia, can NO has been found to play a critical bifunctional role (as a trigger and a mediator) in late PC, a faithfully reproduce the molecular and functional aspects of ischemia-induced late PC. NO-releasing paradigm referred to as the NO hypothesis of late PC. 108 Specifically, enhanced generation of NO by agents (i.e. nitrates) are widely used in patients with coronary artery disease and are generally well eNOS is essential to trigger the late phase of ischemia-induced and exercise-induced PC, and entolerated, and recent studies have demonstrated the ability of nitrates to elicit a state of late PC in patients hanced NO production by iNOS is obligatorily required to mediate the anti-stunning and antias well. 145 Furthermore, recent experimental data indicate that gene transfer of either eNOS 155 or infarct actions of late PC induced by five different stimuli (ischemia, adenosine A 1 agonists, opioid 1 iNOS 156 can replicate the powerful infarct-sparing actions of ischemic PC. The time has come to agonists, endotoxin derivatives, and exercise). The NO hypothesis of late PC has thus revealed a pretranslate the enormous body of experimental work reviewed herein into clinically useful therapies by viously unrecognized cytoprotective function of iNOS in the cardiovascular system. harnessing the cytoprotective properties of NO. The diversity of the PC stimuli that converge on iNOS implies that the upregulation of this enzyme Acknowledgements is a central mechanism whereby the heart protects itself from ischemia, a concept congruous with This study was supported in part by National Inemerging evidence indicating that iNOS is a hystitutes of Health grants R01 HL-43151, HL-55757 poxia-inducible protein. Recent data demonstrating and HL-68088 by the Jewish Hospital Research that iNOS mediates delayed protection in kidney Foundation, Louisville, KY, and by the Comand intestine have extended the NO hypothesis monwealth of Kentucky Research Challenge Trust of late PC beyond the cardiovascular system. A Fund. We gratefully acknowledge Carla Hilse and corollary of this hypothesis is that the heart reMarcia Joines for expert secretarial assistance. sponds to ischemia by utilizing two different NOS isoforms in a manner that is congruous with their properties: it recruits pre-existing eNOS for an imReferences mediate burst of NO production and, at the same time, it upregulates iNOS to switch to a defensive hancement of NO biosynthesis. In the ultimate
